文献速递炎症性肠病

中重度溃疡性结肠炎先进治疗疗效比较:2024年美国胃肠病学协会证据合成

Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
PubMed 文献 · Gastroenterology · 2024-10-18

本文为2024年美国胃肠病学协会(AGA)中重度溃疡性结肠炎(UC)临床指南提供依据的更新系统综述与网状Meta分析,检索至2023年11月21日,纳入比较不同先进疗法与安慰剂或另一种活性对照药的随机对照试验,主要结局为临床缓解的诱导与维持,次要结局为内镜改善,采用频率学方法进行网状Meta分析并用GRADE分级评价证据质量。

要点

  • 在生物制剂初治患者中,低确定性证据支持英夫利西单抗、奥扎尼莫德、瑞莎珠单抗和古塞奇尤单抗在诱导缓解方面优于阿达木单抗和米吉珠单抗,其中瑞莎珠单抗和奥扎尼莫德排名最高。
  • 当JAK抑制剂被纳入一线治疗时,乌帕替尼在诱导缓解方面除奥扎尼莫德和瑞莎珠单抗外优于所有其他药物,证据确定性为低至中等。
  • 在有生物制剂暴露史的患者中,乌帕替尼、托法替布和乌司奴单抗在获得缓解方面排名最高。

核心结论

  • 该更新网状Meta分析采用GRADE评价证据质量,将为中重度UC生物制剂初治和经治患者的先进疗法比较疗效和定位提供依据。

研究设计与样本

  • 更新系统综述与网状Meta分析,检索多个电子数据库截至2023年11月21日,纳入中重度UC成人随机对照试验,比较不同先进疗法与安慰剂或另一种活性对照药。
  • 先进疗法包括肿瘤坏死因子拮抗剂、维得利珠单抗、鞘氨醇-1-磷酸受体调节剂、白细胞介素12/23或选择性白细胞介素23拮抗剂、Janus激酶(JAK)抑制剂。
  • 主要结局为临床缓解的诱导和维持,次要结局为内镜改善;采用频率学方法进行网状Meta分析,并用GRADE评价证据确定性。

主要发现

  • 在生物制剂初治的中重度UC患者中,低确定性证据支持英夫利西单抗、奥扎尼莫德、瑞莎珠单抗和古塞奇尤单抗在诱导治疗获得缓解方面优于阿达木单抗和米吉珠单抗,其中瑞莎珠单抗和奥扎尼莫德排名最高。
  • 当JAK抑制剂被纳入一线治疗时,乌帕替尼在诱导缓解方面除奥扎尼莫德和瑞莎珠单抗外优于所有其他药物,证据确定性为低至中等。
  • 在有生物制剂暴露史的患者中,乌帕替尼、托法替布和乌司奴单抗在获得缓解方面排名最高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We performed an updated systematic review and network meta-analysis to inform the 2024 American Gastroenterological Association (AGA) Clinical Guidelines on the management of moderate-to-severe ulcerative colitis (UC). METHODS: We searched multiple electronic databases through November 21, 2023, to identify randomized controlled trials in adults with moderate-to-severe UC, comparing different advanced therapies (tumor necrosis factor antagonists, vedolizumab, sphingosine-1-phosphate receptor modulators, interleukin 12/23 or selective interleukin 23 antagonists, and Janus kinase [JAK] inhibitors) against placebo or another active comparator. Our primary outcomes were induction and maintenance of clinical remission, and our secondary outcome was endoscopic improvement. We performed a network meta-analysis using a frequentist approach and applied Grading of Recommendations, Assessment, Development and Evaluation (GRADE) to appraise certainty of evidence. RESULTS: After excluding JAK inhibitors as potential first-line treatment (in accordance with the United States Food and Drug Administration), low-certainty evidence supports clinically important benefit with infliximab, ozanimod, risankizumab, and guselkumab over adalimumab and mirikizumab for achieving remission with induction therapy in biologically naïve patients with moderate-to-severe UC, with risankizumab and ozanimod being ranked the highest for induction of clinical remission. With the inclusion of JAK inhibitors as first-line therapy, upadacitinib was more efficacious compared with all other medications except ozanimod and risankizumab, with low- to moderate-certainty evidence. In patients with prior biologic exposure, upadacitinib, tofacitinib, and ustekinumab were ranked highest for achieving remission. CONCLUSIONS: Using Grading of Recommendations, Assessment, Development and Evaluation to appraise quality of evidence, this updated network meta-analysis will be used to inform comparative efficacy and positioning of advanced therapies for the treatment of biologic-naïve and biologic-exposed patients with moderate-to-severe UC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Ananthakrishnan AN, Murad MH, Scott FI, et al. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. Gastroenterology. 2024. PMID: 39425738. doi:10.1053/j.gastro.2024.07.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。